Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Future Oncol
; 17(22): 2923-2939, 2021 Aug.
Article
in En
| MEDLINE
| ID: mdl-33855868
Lay abstract The goal of this study was to compare the health-related quality of life (HRQoL) of patients with advanced unresectable dedifferentiated liposarcoma treated with selinexor compared with those treated with placebo. HRQoL was measured prior to treatment initiation and at the first day of each cycle of their treatment using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Pain scores worsened for placebo compared with selinexor across all visits after treatment, but differences at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms worsened over time reflecting the progressive disease burden in this patient population. As pain is one of the most devastating symptoms associated with advanced and progressing cancers, the significant reduction in pain in the selinexor arm, according to patient perception, represent a relevant added value of this drug in dedifferentiated liposarcoma.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quality of Life
/
Triazoles
/
Cancer Pain
/
Hydrazines
/
Liposarcoma
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
Aspects:
Patient_preference
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Future Oncol
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom